-

Agilent to Present at Upcoming Investor Events; Provides Webcast Details for Annual Shareholder Meeting

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the following webcasts for the investment community.

10th Annual SVB Leerink Global Healthcare Conference
Wednesday, Feb. 24 at 7:40 a.m. Pacific time/10:40 a.m. Eastern time
Bob McMahon, Agilent chief financial officer

41st Annual Cowen And Company Healthcare Conference
Thursday, March 4 at 8:10 Pacific time/11:10 a.m. Eastern time
Mike McMullen, Agilent president and CEO

To access these presentations, a Link will be provided in the “News & Events -- Events” portion of the Investor Relations section of the Agilent website.

In addition, the company announced details for the webcast of Agilent’s Annual Shareholder Meeting March 17. To join the meeting, please see the information below.

Agilent Technologies 2021 Annual Meeting of Shareholders
Wednesday, March 17 at 8 a.m. Pacific time/11 a.m. Eastern time
Virtual Meeting log-in beginning at 7:30 a.m. Pacific time
Virtual Meeting access: www.meetingcenter.io/238392758
Password: A2021

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Investor Contact:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

Media Contact:
Tom Beermann
+1 408-386-5892
tom.beermann@agilent.com

Industry:

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB
Release Summary
Agilent announces upcoming investor events and details for annual Shareholder Meeting.
Release Versions
English
$Cashtags
$A
Hashtags
#Agilent
#AnnualShareholderMeeting
#InvestorEvents

Contacts

Investor Contact:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

Media Contact:
Tom Beermann
+1 408-386-5892
tom.beermann@agilent.com

More News From Agilent Technologies Inc.

Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on behalf of Professor Zongwei Cai. The award recognizes Professor Cai's innovative research focused on developing advanced analytical approaches for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, a growing area of importance for environmental and public health resea...

Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. The company will host a conference call to discuss the results at 1:30 p.m. PDT the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s Investor Relations website. A recording of the call will also be available on the website for 90 days. Abo...

Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s (known as MSD outside the United States and Canada) anti-PD-1 therapy. PD...
Back to Newsroom